Epstein-Barr Virus Vaccine, Phase I

A board to discuss future MS therapies in early stage (Phase I or II) trials.
Post Reply
User avatar
NHE
Volunteer Moderator
Posts: 6211
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Epstein-Barr Virus Vaccine, Phase I

Post by NHE »

Phase I study of an Epstein-Barr Virus (EBV) in healthy volunteers. The vaccine works by targeting EBV glycoprotein gp350, which is found on the surface of the virus and virus-infected cells. EBV gp350 is also the primary target for neutralizing antibodies found in the blood of people naturally infected with EBV. The study is recruiting 40 healthy adults age 18-29.

https://nihrecord.nih.gov/2022/05/27/ni ... rr-vaccine

It’s been 2.5 years since the study was posted to ClinicalTrials.gov and it’s still in the recruiting status.

https://www.clinicaltrials.gov/ct2/show ... w=2&rank=1
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Drug Pipeline”